Xia Zhu

807 total citations
14 papers, 632 citations indexed

About

Xia Zhu is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Xia Zhu has authored 14 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Xia Zhu's work include Lung Cancer Research Studies (4 papers), Sarcoma Diagnosis and Treatment (3 papers) and Peptidase Inhibition and Analysis (3 papers). Xia Zhu is often cited by papers focused on Lung Cancer Research Studies (4 papers), Sarcoma Diagnosis and Treatment (3 papers) and Peptidase Inhibition and Analysis (3 papers). Xia Zhu collaborates with scholars based in China. Xia Zhu's co-authors include Guang‐Xian Zhong, Jianhua Lin, Chaoyang Wu, Jinyuan Chen, Shenglin Wang, Hongxiang Wei, Zhoujie Liu, Jianmin Song, Yongkui Lu and Guowen Wang and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Talanta.

In The Last Decade

Xia Zhu

13 papers receiving 629 citations

Peers

Xia Zhu
W. Shannon Orr United States
Ari J. Rosenberg United States
M. Morell Spain
Xin Sun China
Xia Zhu
Citations per year, relative to Xia Zhu Xia Zhu (= 1×) peers Taisuke Furuta

Countries citing papers authored by Xia Zhu

Since Specialization
Citations

This map shows the geographic impact of Xia Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xia Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xia Zhu more than expected).

Fields of papers citing papers by Xia Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xia Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xia Zhu. The network helps show where Xia Zhu may publish in the future.

Co-authorship network of co-authors of Xia Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Xia Zhu. A scholar is included among the top collaborators of Xia Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xia Zhu. Xia Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Zhu, Xia, et al.. (2023). The clinical signification and application value of [68Ga]Ga-PSMA imaging in thyroid malignancy. Endocrine. 84(2). 598–606. 4 indexed citations
2.
Zhu, Xia, et al.. (2020). COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203. Bioengineered. 11(1). 201–208. 17 indexed citations
4.
Chi, Yihebali, Yang Yao, Zhiwei Fang, et al.. (2020). Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma.. Journal of Clinical Oncology. 38(15_suppl). e23548–e23548. 1 indexed citations
5.
Fang, Zhiwei, Yang Yao, Jianqiang Cai, et al.. (2020). Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status.. Journal of Clinical Oncology. 38(15_suppl). e23562–e23562. 1 indexed citations
6.
Wei, Hongxiang, Jinyuan Chen, Shenglin Wang, et al.. (2019). <p>A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro</p>. International Journal of Nanomedicine. Volume 14. 8603–8610. 249 indexed citations
7.
Chi, Yihebali, Zhiwei Fang, Xiaonan Hong, et al.. (2018). Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 24(21). 5233–5238. 245 indexed citations
8.
Wu, Zhaoyang, Jinyuan Chen, Xia Zhu, et al.. (2018). Sensitive electrochemical cytosensor for highly specific detection of osteosarcoma 143B cells based on graphene-3D gold nanocomposites. Journal of Electroanalytical Chemistry. 824. 108–113. 4 indexed citations
9.
Chi, Yihebali, Yang Yao, Shusen Wang, et al.. (2018). Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.. Journal of Clinical Oncology. 36(15_suppl). 11503–11503. 49 indexed citations
10.
Zhong, Guang‐Xian, et al.. (2017). The clinical significance of the <em>Ezrin</em> gene and circulating tumor cells in osteosarcoma. OncoTargets and Therapy. Volume 10. 527–533. 19 indexed citations
12.
Chi, Yihebali, Yongkun Sun, Jianqiang Cai, et al.. (2016). Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.. Journal of Clinical Oncology. 34(15_suppl). 11005–11005. 21 indexed citations
13.
Zheng, Xiaohong, Wei Li, Xiaolan Yang, et al.. (2015). Antitumour effects of tetrazanbigen against human hepatocellular carcinoma QGY-7701 through inducing lipid accumulation in vitro and in vivo. Journal of Pharmacy and Pharmacology. 67(11). 1593–1602. 8 indexed citations
14.
Zhong, Guang‐Xian, Peng Wang, Shaohuang Weng, et al.. (2014). Electrochemical immunosensor for detection of topoisomerase based on graphene–gold nanocomposites. Talanta. 125. 439–445. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026